Senior executives of the Pharmaceuticals Division of Bayer shared the company's commitment in bringing innovative medicines to Asia Pacific, as well as detailed its growth plans and Research and Development (R&D) pipeline. As part of its commitment to foster collaboration with the healthcare community and academia in addressing the region's healthcare challenges, the Pharmaceuticals Division of Bayer invited other experts in the industry to a dialogue session to discuss the rising incidences of stroke and thrombosis in Asia Pacific, and how to work together to relieve the burden of both in the region.
Presentation by Claus Zieler, Senior Vice President & Head of Commercial Operations, Bayer Pharmaceuticals Division Asia / Pacific
From left to right: Chuan Kit Foo, Head of Medical Affairs, Bayer Pharmaceuticals Division Asia / Pacific, Adj Assoc Prof Tan Ru San, Senior Consultant, Cardiology, National Heart Centre Singapore, Amit Backliwal, Vice President, Technology and Services, IMS Health, China and Southeast Asia, Claus Zieler, Senior Vice President & Head of Commercial Operations, Bayer Pharmaceuticals Division Asia / Pacific
With special thanks to Bayer and Huntington Comms (Photos credit to Bayer)